Igor I. Slukvin, PhD, MD close
Igor I. Slukvin, PhD, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Igor I. Slukvin, PhD, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Igor I. Slukvin, PhD, MD, earned his medical degree from Kiev Medical University in Ukraine and completed his residency at UW Hospital and Clinics.




University Hospital
(608) 263-8443 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Pathology and Laboratory Medicine

Professional Certifications and Education

Board Certification Anatomic Pathology & Clinical Pathology
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Medical School Kiev International Medical University, Kiev, Ukraine

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
Kumar A Lee JH Suknuntha K D'Souza SS Thakur AS Slukvin II NOTCH Activation at the Hematovascular Mesoderm Stage Facilitates Efficient Generation of T Cells with High Proliferation Potential from Human Pluripotent Stem Cells. J Immunol . 2018 Dec 21;
[PubMed ID: 30578305]
Slukvin II Uenishi GI Arterial identity of hemogenic endothelium: a key to unlock definitive hematopoietic commitment in hPSC cultures. Exp Hematol . 2018 Nov 28;
[PubMed ID: 30500414]
Park MA Jung HS Slukvin I Genetic Engineering of Human Pluripotent Stem Cells Using PiggyBac Transposon System. Curr Protoc Stem Cell Biol . 2018 Nov;47(1):e63
[PubMed ID: 30281932]
Suknuntha K Tao L Brok-Volchanskaya V D'Souza SS Kumar A Slukvin I Optimization of Synthetic mRNA for Highly Efficient Translation and its Application in the Generation of Endothelial and Hematopoietic Cells from Human and Primate Pluripotent Stem Cells. Stem Cell Rev . 2018 Aug;14(4):525-534
[PubMed ID: 29520567]
Slukvin II Kumar A The mesenchymoangioblast, mesodermal precursor for mesenchymal and endothelial cells. Cell Mol Life Sci . 2018 Jul 10;
[PubMed ID: 29992471]
Kang H Mesquitta WT Jung HS Moskvin OV Thomson JA Slukvin II GATA2 Is Dispensable for Specification of Hemogenic Endothelium but Promotes Endothelial-to-Hematopoietic Transition. Stem Cell Reports . 2018 Jul 10;11(1):197-211
[PubMed ID: 29861167]
Park MA Kumar A Jung HS Uenishi G Moskvin OV Thomson JA Slukvin II Activation of the Arterial Program Drives Development of Definitive Hemogenic Endothelium with Lymphoid Potential. Cell Rep . 2018 May 22;23(8):2467-2481
[PubMed ID: 29791856]
Uenishi GI Jung HS Kumar A Park MA Hadland BK McLeod E Raymond M Moskvin O Zimmerman CE Theisen DJ Swanson S J Tamplin O Zon LI Thomson JA Bernstein ID Slukvin II NOTCH signaling specifies arterial-type definitive hemogenic endothelium from human pluripotent stem cells. Nat Commun . 2018 May 8;9(1):1828
[PubMed ID: 29739946]
D'Souza SS Kumar A Slukvin II Functional Heterogeneity of Endothelial Cells Derived from Human Pluripotent Stem Cells. Stem Cells Dev . 2018 Apr 15;27(8):524-533
[PubMed ID: 29583085]
Kumar A D'Souza SS Moskvin OV Toh H Wang B Zhang J Swanson S Guo LW Thomson JA Slukvin II Specification and Diversification of Pericytes and Smooth Muscle Cells from Mesenchymoangioblasts. Cell Rep . 2017 May 30;19(9):1902-1916
[PubMed ID: 28564607]
Suknuntha K Thita T Togarrati PP Ratanachamnong P Wongtrakoongate P Srihirun S Slukvin I Hongeng S Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines. Int J Hematol . 2017 Feb;105(2):196-205
[PubMed ID: 27766528]
Eguchi A Wleklinski MJ Spurgat MC Heiderscheit EA Kropornicka AS Vu CK Bhimsaria D Swanson SA Stewart R Ramanathan P Kamp TJ Slukvin I Thomson JA Dutton JR Ansari AZ Reprogramming cell fate with a genome-scale library of artificial transcription factors. Proc Natl Acad Sci U S A . 2016 Dec 20;113(51):E8257-E8266
[PubMed ID: 27930301]
Slukvin II Generating human hematopoietic stem cells in vitro -exploring endothelial to hematopoietic transition as a portal for stemness acquisition. FEBS Lett . 2016 Nov;590(22):4126-4143
[PubMed ID: 27391301]
Jung HS Uenishi G Kumar A Park MA Raymond M Fink D McLeod E Slukvin I A human VE-cadherin-tdTomato and CD43-green fluorescent protein dual reporter cell line for study endothelial to hematopoietic transition. Stem Cell Res . 2016 Sep;17(2):401-405
[PubMed ID: 27879215]
Hafner AL Contet J Ravaud C Yao X Villageois P Suknuntha K Annab K Peraldi P Binetruy B Slukvin II Ladoux A Dani C Brown-like adipose progenitors derived from human induced pluripotent stem cells: Identification of critical pathways governing their adipogenic capacity. Sci Rep . 2016 Aug 31;6:32490
[PubMed ID: 27577850]
D'Souza SS Maufort J Kumar A Zhang J Smuga-Otto K Thomson JA Slukvin II GSK3β Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells. Stem Cell Reports . 2016 Feb 9;6(2):243-56
[PubMed ID: 26805448]
Kang H Minder P Park MA Mesquitta WT Torbett BE Slukvin II CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids . 2015 Dec 15;4:e268
[PubMed ID: 26670276]
Elcheva I Brok-Volchanskaya V Slukvin I Direct Induction of Hemogenic Endothelium and Blood by Overexpression of Transcription Factors in Human Pluripotent Stem Cells. J Vis Exp . 2015 Dec 3;(106):e52910
[PubMed ID: 26710184]
Suknuntha K Ishii Y Tao L Hu K McIntosh BE Yang D Swanson S Stewart R Wang JYJ Thomson J Slukvin I Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res . 2015 Nov;15(3):678-693
[PubMed ID: 26561938]
McIntosh BE Brown ME Duffin BM Maufort JP Vereide DT Slukvin II Thomson JA Nonirradiated NOD,B6.SCID Il2rγ-/- Kit(W41/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells. Stem Cell Reports . 2015 Feb 10;4(2):171-80
[PubMed ID: 25601207]